Zhao X, Song L, Wang Y, Li J, Zhou J, Chen R, . . . Yan H. (2021). Proprotein Convertase Subtilisin/Kexin Type 9 and Systemic Inflammatory Biomarker Pentraxin 3 for Risk Stratification Among STEMI Patients Undergoing Primary PCI. Dove Medical Press.
Chicago Style (17th ed.) CitationZhao X, et al. Proprotein Convertase Subtilisin/Kexin Type 9 and Systemic Inflammatory Biomarker Pentraxin 3 for Risk Stratification Among STEMI Patients Undergoing Primary PCI. Dove Medical Press, 2021.
MLA (9th ed.) CitationZhao X, et al. Proprotein Convertase Subtilisin/Kexin Type 9 and Systemic Inflammatory Biomarker Pentraxin 3 for Risk Stratification Among STEMI Patients Undergoing Primary PCI. Dove Medical Press, 2021.
Warning: These citations may not always be 100% accurate.